Intuit (INTU) – Research Analysts’ Weekly Ratings Changes

A number of firms have modified their ratings and price targets on shares of Intuit (NASDAQ: INTU) recently:

  • Intuit had its price target raised by analysts at Macquarie from $60.00 to $62.00. They now have a “neutral” rating on the stock.
  • Intuit had its price target raised by analysts at UBS AG from $67.00 to $69.00. They now have a “buy” rating on the stock.
  • Intuit had its price target raised by analysts at Barclays Capital from $65.00 to $67.00. They now have an “equal weight” rating on the stock.
  • Intuit had its price target raised by analysts at Wedbush from $72.00 to $76.00. They now have an “outperform” rating on the stock.
  • Intuit had its “neutral” rating reaffirmed by analysts at Goldman Sachs.
  • Intuit had its price target raised by analysts at Raymond James from $65.00 to $68.00.

Shares of Intuit traded up 1.00% during mid-day trading on Tuesday, hitting $62.64. Intuit has a one year low of $53.38 and a one year high of $64.47. The stock’s 50-day moving average is currently $62.56. The company has a market cap of $18.541 billion and a P/E ratio of 23.71.

Intuit Inc. (Intuit) is a provider of business and financial management solutions for small businesses, consumers, accounting professionals and financial institutions.

Leave a Reply

Recent Stories

Liver Disease Risk Might be Lowered by Drinking Coffee
Liver Disease Risk Might be Lowered by Drinking Coffee
Construction Workers in Dubai Strike for Better Pay and Overtime
Construction Workers in Dubai Strike for Better Pay and Overtime
Bashar al-Assad says no to Stepping Down as Syria President
Bashar al-Assad says no to Stepping Down as Syria President
CDC: Mental Disorders affect close to 1 out of 5 Children
CDC: Mental Disorders affect close to 1 out of 5 Children
Airplanes and Airlines to be filled to Capacity this Summer
Airplanes and Airlines to be filled to Capacity this Summer
Erectile Dysfunction Tied to Pain Killer Medication
Erectile Dysfunction Tied to Pain Killer Medication
© 2010-2013 The Utah People's Post, Inc. · RSS. · Subscribe Subscribe